Showing 6451-6460 of 7464 results for "".
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Regenerative Medicine Breakthrough: Mobile Bedside Bioprinter May Heal Woundshttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-mobile-bedside-bioprinter-may-heal-wounds/2459876/Researchers have created a mobile skin bioprinting system that allows bi-layered skin to be printed directly into a wound. The team demonstrated proof-of-concept of the system by printing skin directly onto pre-clinical models, and the next step is to conduct a clinical trial in humans, t
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo
- FDA Proposes New Sunscreen Regulations; Experts Reacthttps://practicaldermatology.com/news/fda-proposes-new-sunscreen-regulations-experts-react/2459889/The FDA is updating its position on over-the-counter sunscreens, and according to the
- Physician Burnout Rates Fall Modestlyhttps://practicaldermatology.com/news/physician-burnout-rates-fall-modestly/2459892/The burnout rate among physicians in the United States has dropped, but there remains significant room for improvement, new data suggest. The burnout rate dropped modestly in 2017 from its peak in 2014. Current burnout rates are in line with 2011 levels. The triennial s
- Dermatology Drugs Market to Reach $34.5 Billion by 2023https://practicaldermatology.com/news/dermatology-drugs-market-to-reach-345-billion-by-2023/2459895/The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their
- New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloidshttps://practicaldermatology.com/news/new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids/2459897/Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines<